153 related articles for article (PubMed ID: 31565482)
21. The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma.
Visser HP; Gunster MJ; Kluin-Nelemans HC; Manders EM; Raaphorst FM; Meijer CJ; Willemze R; Otte AP
Br J Haematol; 2001 Mar; 112(4):950-8. PubMed ID: 11298590
[TBL] [Abstract][Full Text] [Related]
22. P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.
Shirsath NP; Manohar SM; Joshi KS
Mol Cancer; 2012 Oct; 11():77. PubMed ID: 23075291
[TBL] [Abstract][Full Text] [Related]
23. Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors.
Yang X; Li F; Konze KD; Meslamani J; Ma A; Brown PJ; Zhou MM; Arrowsmith CH; Kaniskan HÜ; Vedadi M; Jin J
J Med Chem; 2016 Aug; 59(16):7617-33. PubMed ID: 27468126
[TBL] [Abstract][Full Text] [Related]
24. p53 directly downregulates the expression of CDC20 to exert anti-tumor activity in mantle cell lymphoma.
Chen Y; Yang P; Wang J; Gao S; Xiao S; Zhang W; Zhu M; Wang Y; Ke X; Jing H
Exp Hematol Oncol; 2023 Mar; 12(1):28. PubMed ID: 36882855
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic silencing of miR-26A1 in chronic lymphocytic leukemia and mantle cell lymphoma: Impact on EZH2 expression.
Kopparapu PK; Bhoi S; Mansouri L; Arabanian LS; Plevova K; Pospisilova S; Wasik AM; Croci GA; Sander B; Paulli M; Rosenquist R; Kanduri M
Epigenetics; 2016 May; 11(5):335-43. PubMed ID: 27052808
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-506 inhibits the proliferation and invasion of mantle cell lymphoma cells by targeting B7H3.
Zhu XW; Wang J; Zhu MX; Wang YF; Yang SY; Ke XY
Biochem Biophys Res Commun; 2019 Jan; 508(4):1067-1073. PubMed ID: 30553455
[TBL] [Abstract][Full Text] [Related]
27. Akt inhibition synergizes with polycomb repressive complex 2 inhibition in the treatment of multiple myeloma.
Rizk M; Rizq O; Oshima M; Nakajima-Takagi Y; Koide S; Saraya A; Isshiki Y; Chiba T; Yamazaki S; Ma A; Jin J; Iwama A; Mimura N
Cancer Sci; 2019 Dec; 110(12):3695-3707. PubMed ID: 31571328
[TBL] [Abstract][Full Text] [Related]
28. Divergent Requirements for EZH1 in Heart Development Versus Regeneration.
Ai S; Yu X; Li Y; Peng Y; Li C; Yue Y; Tao G; Li C; Pu WT; He A
Circ Res; 2017 Jul; 121(2):106-112. PubMed ID: 28512107
[TBL] [Abstract][Full Text] [Related]
29. Ezh1 and Ezh2 differentially regulate PSD-95 gene transcription in developing hippocampal neurons.
Henriquez B; Bustos FJ; Aguilar R; Becerra A; Simon F; Montecino M; van Zundert B
Mol Cell Neurosci; 2013 Nov; 57():130-43. PubMed ID: 23932971
[TBL] [Abstract][Full Text] [Related]
30. Deregulation of Polycomb Repressive Complex-2 in Mantle Cell Lymphoma Confers Growth Advantage by Epigenetic Suppression of
Demosthenous C; Gupta SK; Sun J; Wang Y; Troska TP; Gupta M
Front Oncol; 2020; 10():1226. PubMed ID: 32850364
[TBL] [Abstract][Full Text] [Related]
31. Chromatin regulated interchange between polycomb repressive complex 2 (PRC2)-Ezh2 and PRC2-Ezh1 complexes controls myogenin activation in skeletal muscle cells.
Stojic L; Jasencakova Z; Prezioso C; Stützer A; Bodega B; Pasini D; Klingberg R; Mozzetta C; Margueron R; Puri PL; Schwarzer D; Helin K; Fischle W; Orlando V
Epigenetics Chromatin; 2011 Sep; 4():16. PubMed ID: 21892963
[TBL] [Abstract][Full Text] [Related]
32. Ezh2 Regulates Activation-Induced CD8
Chen G; Subedi K; Chakraborty S; Sharov A; Lu J; Kim J; Mi X; Wersto R; Sung MH; Weng NP
Front Immunol; 2018; 9():549. PubMed ID: 29632530
[TBL] [Abstract][Full Text] [Related]
33. CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells.
Yang X; Karuturi RK; Sun F; Aau M; Yu K; Shao R; Miller LD; Tan PB; Yu Q
PLoS One; 2009; 4(4):e5011. PubMed ID: 19340297
[TBL] [Abstract][Full Text] [Related]
34. Ezh1 Targets Bivalent Genes to Maintain Self-Renewing Stem Cells in Ezh2-Insufficient Myelodysplastic Syndrome.
Aoyama K; Oshima M; Koide S; Suzuki E; Mochizuki-Kashio M; Kato Y; Tara S; Shinoda D; Hiura N; Nakajima-Takagi Y; Sashida G; Iwama A
iScience; 2018 Nov; 9():161-174. PubMed ID: 30396150
[TBL] [Abstract][Full Text] [Related]
35. [Prognostic significance of miRNA-223 targeting SOX11 in mantle cell lymphoma].
Zhang Q; Zhang WT; Wu SS; Yuan JJ; Tian L; Liu YY; Zuo WL; Song YP; Zhou KS
Zhonghua Xue Ye Xue Za Zhi; 2018 Jul; 39(7):579-583. PubMed ID: 30122018
[No Abstract] [Full Text] [Related]
36. Six Years (2012-2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2-Pyridone Compounds.
Fioravanti R; Stazi G; Zwergel C; Valente S; Mai A
Chem Rec; 2018 Dec; 18(12):1818-1832. PubMed ID: 30338896
[TBL] [Abstract][Full Text] [Related]
37. Long noncoding RNA UPK1A-AS1 indicates poor prognosis of hepatocellular carcinoma and promotes cell proliferation through interaction with EZH2.
Zhang DY; Sun QC; Zou XJ; Song Y; Li WW; Guo ZQ; Liu SS; Liu L; Wu DH
J Exp Clin Cancer Res; 2020 Oct; 39(1):229. PubMed ID: 33121524
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
[TBL] [Abstract][Full Text] [Related]
39. [Novel epigenetic therapies for multiple myeloma].
Mimura N
Rinsho Ketsueki; 2021; 62(4):314-320. PubMed ID: 33967157
[TBL] [Abstract][Full Text] [Related]
40. Ezh1 is required for hematopoietic stem cell maintenance and prevents senescence-like cell cycle arrest.
Hidalgo I; Herrera-Merchan A; Ligos JM; Carramolino L; Nuñez J; Martinez F; Dominguez O; Torres M; Gonzalez S
Cell Stem Cell; 2012 Nov; 11(5):649-62. PubMed ID: 23122289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
